248 related articles for article (PubMed ID: 20941740)
1. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
2. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
[TBL] [Abstract][Full Text] [Related]
3. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
4. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
[TBL] [Abstract][Full Text] [Related]
5. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.
Getman D; Aiyer A; Dockter J; Giachetti C; Zhang F; Ginocchio CC
J Clin Virol; 2009 Jul; 45 Suppl 1():S49-54. PubMed ID: 19651369
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
[TBL] [Abstract][Full Text] [Related]
7. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology.
Castle PE; Reid J; Dockter J; Getman D
J Clin Virol; 2015 Aug; 69():52-5. PubMed ID: 26209379
[TBL] [Abstract][Full Text] [Related]
8. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
[TBL] [Abstract][Full Text] [Related]
9. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.
Castle PE; Eaton B; Reid J; Getman D; Dockter J
J Clin Microbiol; 2015 Apr; 53(4):1277-81. PubMed ID: 25653409
[TBL] [Abstract][Full Text] [Related]
10. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial.
Cook DA; Smith LW; Law JH; Mei W; Gondara L; van Niekerk DJ; Ceballos KM; Jang D; Chernesky M; Franco EL; Ogilvie GS; Coldman AJ; Krajden M
J Clin Virol; 2018 Nov; 108():32-37. PubMed ID: 30223252
[TBL] [Abstract][Full Text] [Related]
11. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.
Wu R; Belinson SE; Du H; Na W; Qu X; Wu R; Liu Y; Wang C; Zhou Y; Zhang L; Belinson JL
Int J Gynecol Cancer; 2010 Nov; 20(8):1411-4. PubMed ID: 21051986
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China.
Zhao FH; Hu SY; Bian JJ; Liu B; Peck RB; Bao YP; Pan QJ; Frappart L; Sellors J; Qiao YL
Cancer Cytopathol; 2011 Dec; 119(6):387-94. PubMed ID: 21774094
[TBL] [Abstract][Full Text] [Related]
14. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.
Clad A; Reuschenbach M; Weinschenk J; Grote R; Rahmsdorf J; Freudenberg N
J Clin Microbiol; 2011 Mar; 49(3):1071-6. PubMed ID: 21191046
[TBL] [Abstract][Full Text] [Related]
15. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women.
Wang J; Du Y; Dong J; Zhou Y; Wang P; Zhang X; Chen Y; He P
Gynecol Oncol; 2019 Apr; 153(1):34-40. PubMed ID: 30630629
[TBL] [Abstract][Full Text] [Related]
17. Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain.
Ibáñez R; Mareque M; Granados R; Andía D; García-Rojo M; Quílez JC; Oyagüez I
BMC Womens Health; 2021 Apr; 21(1):178. PubMed ID: 33902553
[TBL] [Abstract][Full Text] [Related]
18. Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China.
Zhang J; Yang D; Cui X; Liu G; Cui Z; Wang C; Piao H
Front Cell Infect Microbiol; 2022; 12():935071. PubMed ID: 36105144
[TBL] [Abstract][Full Text] [Related]
19. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]